dc.contributor.advisor | Bustos, Rosa Helena | |
dc.contributor.advisor | León Delgado, Marta Ximena | |
dc.contributor.advisor | Jaimes, Diego | |
dc.contributor.author | Arias Villate, Sara Consuelo | |
dc.date.accessioned | 2020-10-01T14:28:48Z | |
dc.date.available | 2020-10-01T14:28:48Z | |
dc.date.issued | 2020-08-14 | |
dc.identifier.uri | http://hdl.handle.net/10818/43439 | |
dc.description | 21 páginas | es_CO |
dc.description.abstract | El Cannabis ha sido usado ampliamente como planta medicinal durante milenios, sin embargo, los estudios relacionados con sus principales componentes comenzaron en 1960. A partir de este momento, los laboratorios comenzaron a producir nuevos componentes y estructuras relacionadas con propiedades biológicas activas. Los países que han aprobado su uso medicinal, cuentan con normatividades que rigen su uso clínico y científico. Adicionalmente, una de las formas de administrar el cannabis medicinal es mediante fórmulas magistrales que deben contar siempre con una prescripción médica, deben ser elaboradas en un establecimiento que cumpla con estándares de calidad que aseguren las cantidades de sus componentes principales como tetrahidrocannabinol (THC) y cannabidol (CBD); adicionalmente deben contar con una indicación clara de su uso en el paciente previo a la prescripción. | es_CO |
dc.format | application/pdf | es_CO |
dc.language.iso | spa | es_CO |
dc.publisher | Universidad de La Sabana | es_CO |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | Universidad de La Sabana | es_CO |
dc.source | Intellectum Repositorio Universidad de La Sabana | es_CO |
dc.title | Evidencia clínica de las fórmulas magistrales basadas en cannabis medicinal en tres indicaciones claves: una revisión panorámica de la literatura | es_CO |
dc.type | bachelor thesis | es_CO |
dc.identifier.local | 278498 | |
dc.identifier.local | TE10903 | |
dc.type.hasVersion | publishedVersion | es_CO |
dc.rights.accessRights | restrictedAccess | es_CO |
dc.subject.armarc | Educación médica | spa |
dc.subject.armarc | Cannabis | spa |
dc.subject.armarc | Medicina clínica -- Investigaciones | spa |
dcterms.references | Bridgeman M, Abazia D. Medicinal Cannabis: History, Pharmacology, And Implications
for the Acute Care Setting. P&T. 2017;42(3):180-8. | eng |
dcterms.references | National Academies of Sciences, Engineering, and Medicine; Health and Medicine
Division; Board on Population Health and Public Health Practice; Committee on the Health
Effects of Marijuana: An Evidence Review and Research Agenda.. 2017. The Health Effects of
Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for
Research. The National Academies Collection: Reports funded by National Institutes of Health.
Washington (DC). | eng |
dcterms.references | Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the
National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018;49:7-
11. | eng |
dcterms.references | Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA.
2015;313(24):2456-73. | eng |
dcterms.references | Scheepers HP LJ, Handlos V, Walser S, Schutjens MH, Neef C. Legislation on the
preparation of medicinal products in European pharmacies and the Council of Europe
Resolution. Eur J Hosp Pharm. 2017;24:224-9. | eng |
dcterms.references | Thomas BF, Pollard GT. Preparation and Distribution of Cannabis and Cannabis-Derived
Dosage Formulations for Investigational and Therapeutic Use in the United States. Front
Pharmacol. 2016;7:285. | eng |
dcterms.references | Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O. An Update of
Current Cannabis-Based Pharmaceuticals in Pain Medicine. Pain Ther. 2019;8(1):41-51. | eng |
dcterms.references | MacCallum CA, Russo EB. Practical considerations in medical cannabis administration
and dosing. Eur J Intern Med. 2018;49:12-9. | eng |
dcterms.references | Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and
Psychiatric Problems: A Clinical Review. JAMA. 2015;313(24):2474-83. | eng |
dcterms.references | Vemuri V, Makriyannis A. Medicinal Chemistry of Cannabinoids. Clinical Pharmacology
and Therapeutics. 2015;97(6). | eng |
dcterms.references | Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, et al. PRISMA-Equity 2012
extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS Med.
2012;9(10):e1001333. | eng |
dcterms.references | Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app
for systematic reviews. Syst Rev. 2016;5(1):210. | eng |
dcterms.references | The Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ Manual: 2015 edition /
Supplement. 2015. | eng |
dcterms.references | Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M. Preferred Reporting
Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement.
Systematic Reviews. 2015;4(1). | eng |
dcterms.references | Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension
for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med.
2018;169(7):467-73. | eng |
dcterms.references | Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and
mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013(4):CD005175. | eng |
dcterms.references | Ungerleider J, Sarna G, Fairbanks L, Goodnight J, Andrysiak T, Jamison K. THC or
Compazine for the cancer chemotherapy patient--the UCLA study. Part II: Patient drug
preference. Am J Clin Oncol. 1985;8(2):142-7. | eng |
dcterms.references | Orr L, McKernan J. Antiemetic Effect of d-9-Tetrahydrocannabinol in ChemotherapyAssociated nausea and Emesis As Compared to Placebo and Compazin. J Clin Pharmacol 1981. | eng |
dcterms.references | Frytak S, Moertel C, O’Fallon J, Rubin J, Creagan E, O’Connell M. Delta-9-
Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer Chemotherapy. . Annals
of Internal Medicine. 1981;91(825-830). | eng |
dcterms.references | Health Canada. Cannabis and the cannabinoids. 2018. | eng |
dcterms.references | Temple LM, Lampert SL, Ewigman B. Barriers to Achieving Optimal Success with
Medical Cannabis: Opportunities for Quality Improvement. J Altern Complement Med.
2019;25(1):5-7 | eng |
dcterms.references | Brunetti P, Pichini S, Pacifici R, Busardo FP, Del Rio A. Herbal Preparations of Medical
Cannabis: A Vademecum for Prescribing Doctors. Medicina (Kaunas). 2020;56(5). | eng |
dcterms.references | Pauli CS, Conroy M, Vanden Heuvel BD, Park SH. Cannabidiol Drugs Clinical Trial
Outcomes and Adverse Effects. Front Pharmacol. 2020;11:63. | eng |
dcterms.references | Leal-Galicia P BD, González-González A, Romo-Parra H. Breve historia sobre la
marihuana en Occidente. Revista de Neurología. 2018;67:133-40 | spa |
dcterms.references | Consejo General de Colegios Oficiales de Farmacéuticos. Procedimiento de Formulación
Magistral. Buenas Prácticas en Farmacia Comunitaria en España. 2017. | spa |
dcterms.references | Ministerio de Salud y Protección Social de Colombia. Decreto 613 de 2017. 2017. | spa |
dcterms.references | Granda E. Formulación magistral. Farmacia Profesional. 2004;18(10):8-11. | spa |
dcterms.references | Ministerio de Salud y Protección Social de Colombia. Resolución 1478 de 2006. 2006. | spa |
dcterms.references | Congreso de la Republica de Colombia. Decreto 677 de 2015. 2015. | spa |
dcterms.references | Congreso de la Republica de Colombia. Ley 1787 de 2016. 2017. | spa |
dcterms.references | Ministerio de Salud y Protección Social. Resolución 2892 de 2017. 2017. | spa |
dcterms.references | Ministerio de salud y Protección Social. Resolución 315 de 2020. 2020. | spa |
thesis.degree.discipline | Facultad de Medicina | es_CO |
thesis.degree.level | Especialización en Farmacología Clínica | es_CO |
thesis.degree.name | Especialista en Farmacología Clínica | es_CO |